|8063062||Compounds with a combination of cannabinoid-CBantagonism and acetylcholinesterase inhibition|
Embodiments of this invention relate to compounds having a combination of cannabinoid-CB1 antagonism and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing ...
The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, (1-5C)heteroaryl R2, R3 are indep...
|7964611||Process for making alkaline earth metal borated sulfonates|
An alkaline earth metal borated sulfonate prepared by a process comprising reacting a mixture of the following materials (A) (1) at least one of an oil soluble sulfonic acid or alkaline earth sulfonate salt or mixtures thereof (2) at least one source of an alkaline ...
Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.
|7728001||Opioid receptor ligands and methods for their preparation|
The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated wi...
|7622478||1-nitroacridine/tumor inhibitor compositions|
The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases. ...
|7423046||3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors|
Compounds of formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meaning indicated in the description, are novel effective PDE4 inhibitors. ...
|7388017||Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease|
The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, eith...
|7354928||Small molecule inhibitors targeted at Bcl-2|
The present invention relates to small molecule antagonists of Bcl-2 family proteins such as Bcl-2 and/or Bcl-XL. In particular, the present invention provides non-peptide cell permeable small molecules (e.g., tricyclo-dibenzo-diazocine-dioxides) that bin...
|7338976||Heterocyclic esters or amides for vision and memory disorders|
This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using heterocyclic esters and amides. ...
|7312082||Crystal structure of G-quadruplex containing a potassium ion|
The present invention relates to a crystal structure of G-quadruplexes and its use. The invention provides a crystal of an intramolecular G-quadruplex structure having a hexagonal space group P6, and unit cell dimensions a=b=56.7 and c=42.1; α=β=90°, γ=120° and...
|7312209||Acridone inhibitors of IMPDH enzyme|
Compounds having the formula (I), wherein R3 is selected from H, OH and NH2; R30 is selected from ═O and ═S; W is —C(═O)—, —S(═O)—, or —S(O)2—; or W...
|7300930||Therapeutic acridone and acridine compounds|
The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a doubl...
|7288533||Topical application for treating toenail fungus|
A topical applications is used to treat and prevent the spread of nail infections or onychomycosis caused by bacteria, fungi and other pathogens. The topical application has a composition that comprises, as an active ingredient, at least one species selected from th...
|7265150||Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders|
This invention relates to novel compositions and uses of N-heterocyclic carboxylic acids and carboxylic acid isosteres for treating a vision disorder, improving vision, treating memory impairment or enhancing memory performance in an animal. ...
|7230105||9-aminoacridine derivatives and process for the preparation thereof|
The present invention relates to a new 9-aminoacridine derivative which exhibits prominent antitumor activity and low toxicity. ...
|7207550||Elevator, procedure for the maintenance of the elevator, procedure for the modernization of an elevator and clamping device for an elevator|
An elevator having a car and a suspension member or respectively hoisting member for carrying an operating weight. Furthermore, a power transmission is intended for moving the suspension member and the hoisting member over at least one moving surface of the power tr...
|7205311||Therapeutic acridone and acridine compounds|
This invention pertains to certain acridone and acridine compounds of the formula which inhibit telomerase, regulate cell proliferation, etc., and/or treat cancer, proliferative conditions, etc.: wherein either: (a) K is ═O, L is —H, alpha single bond, beta is a...
This invention relates to treating inflammatory and immune diseases with certain aminoquinoline compounds that bind to CXCR3 receptors. The aminoquinoline compounds are covered by the formula (I) shown below. Each variable is defined in the specification.
|7160896||Therapeutic acridone and acridine compounds|
The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bon...
|7141581||Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use|
Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit un...
|7139565||Connection architecture for a mobile network|
A real-time communication architecture establishes a continuous connection between an enterprise network and a communication management system. The connection is continuously held open allowing mobile devices real-time access to enterprise email systems. The real-ti...
|7094378||Method and apparatus for inactivation of biological contaminants using photosensitizers|
Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusti...
|7084106||Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease|
The present invention provides a novel treatment for senile dementia (Alzheimer's Type), comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the prod...
|7060711||Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HTreceptor antagonist|
The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease stat...
|7041674||Carbamic acid esters with anticholinergic activity|
A compound of formula 1 wherein X−, A, R1, R2, R3, and R4 may have the meanings given in the claims and in the specification, processes for preparing them, their...
|7033604||Composition for topical administration|
The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as shown by the general formula ...
|7030133||Inhibitors of formation of advanced glycation endproducts (AGEs)|
The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood an...
|7030132||Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs|
A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to an orally administered pharmaceutically active compound, wherein a bioenhancer comprising an inhibitor of BCRP is orally administered concomitantly with said orally ...
|7022855||Halogen-substituted quinoline derivatives and ectoparasite control agent|
An objective of the present invention is to provide an ectoparasite control agent for homothermic animals, which has high control effect and is safe. The compounds according to the present invention are compounds represented by formula (I) and salts thereof:
|7019015||Fungicide for plants|
A fungicidal composition and method of treating plant diseases using a compound of the formula I. ...
Process for preparing 3-[(4S)-5-oxo-2-(trifluoromethyl)-1,4,5,6,7,8-hexahydroquinolin-4-yl]benzonitrile, pharmaceutical compositions containing the compound and methods of treatment using the same. ...
|6998405||Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use|
Compounds of the general formula I wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic...
|6974821||Methods for treating neuropsychiatric disorders|
The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administ...
|6956043||Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions|
A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium. ...
|6936583||Method and compositions for administering taxanes orally to human patients|
Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood level...
|6906081||Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders|
This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H3 receptor antagonist/m2 muscarinic antagonist, or a combination ...
Compounds of formula 1, in which Het is an unsubstituted or R6- and/or R7-substituted pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyrazinyl or pyradazinyl radical, or an unsubstitute...
Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C1 are bivalent radicals, and precursors of the radicals B and B1
|6867197||Method of targeting conjugate molecules to mitochondria|
The present invention relates to genetic mutations in mitochondrial cytochrome c oxidase genes that segregate with Alzheimer's disease (AD). The invention provides methods for detecting such mutations, as a diagnostic for Alzheimer's Disease, either before or after ...